The FDA has granted approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with Waldenstrom macroglobulinemia (WM). "Bruton tyrosine kinase (BTK) inhibition is an emerging standard of care for WM," wrote Constantine Si Lun Tam, MBBS, MD, FRACP, FRCPA, Professor at the Peter MacCallum Cancer Centre in Australia, and colleagues, in their publication of the ASPEN study results (NCT03053440), on which the approval was based. "ASPEN is a randomized phase 3 study comparing zanubru...

Non-Hodgkin lymphoma (NHL) is one of the most common cancers, comprising 4% of all cancers in the United States. Although non-Hodgkin lymphoma can occur at any age, more than half of all patients are 65 years old or older. Efforts are ongoing to find new and better ways to treat non-Hodgkin lymphoma. In this interview, Maria Badillo, MSN, RN, OCN®, CCRP, a Research Nurse Manager at The University of Texas MD Anderson Cancer Center, talks about the challenges and strategies involving the nursing ...

The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...

Waldenström macroglobulinemia is a rare lymphoproliferative disorder, with an estimated 1,500 new cases reported in the United States each year. This malignancy, which accounts for 2% of non-Hodgkin lymphomas, is characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM). It is important for health care professionals involved in the care of patients with Waldenström macroglobulinemia to remain up to date in their knowledge of risk stra...

Complete surgical resection prior to immunochemotherapy may benefit patients with diffuse large B-cell lymphoma (DLBCL) under the age of 60, according to results from a subgroup analysis of the phase 3 PETAL trial. Unlike the treatment of solid tumors, the treatment of lymphoma focuses almost exclusively on systemic therapy. Surgical resection is generally only performed for diagnostic value, and little evidence exists regarding its impact on outcomes for patients with lymphoma. "Modern imaging ...